Novocuff, Inc.

Novocuff, Inc. is a clinical-stage maternal health medical device company based in Mountain View, California, building the Novocuff Cervical Control System (CCS) - a device designed to stabilize and close the cervix, retain amniotic fluid, and extend pregnancy in cases of preterm prelabor rupture of membranes (PPROM) and cervical shortening. Founded in 2021 by Amelia Degenkolb and Donald Lee, the company raised an oversubscribed $26M Series A in 2024 (about $28M total) to fund its U.S. multicenter pivotal RETAIN trial, for which it secured FDA IDE approval in September 2025.